Healthcare AI buying now needs governance from day one. I’d sum it up like this: if a tool can touch PHI, draft chart notes, guide care, or change over time, I need more than a price review, a security form, and a contract.
By 2024, 71% of non-federal acute-care hospitals said they were using predictive AI in their EHRs. And 31.5% reported current use of generative AI in the EHR, with another 24.7% planning to add it within a year. That means procurement is no longer just a buying step. It’s where I need to check clinical risk, data use, bias, vendor accountability, and post-launch review before a tool goes live.
Here’s the article in plain English:
- Old vendor review is not enough for AI that can change after rollout.
- I need risk tiering so low-risk tools move fast and high-risk tools get deeper review.
- I should check model details, PHI flows, subgroup testing, human review steps, audit logs, and outside dependencies before approval.
- Contracts need terms for model updates, incident notice, PHI use limits, audit rights, deletion, and subcontractor disclosure.
- Approval is only the start. High-risk tools need repeat review, drift checks, incident tracking, and dashboard reporting after launch.
If I had to boil the whole piece down to one line, it would be this: AI procurement in healthcare is now a lifecycle control process, not a one-time checklist.
From Principles to Practice Exploring AI Governance in Health Systems
Why Legacy Procurement Processes Miss AI-Specific Risk
Legacy procurement still tends to review products as if they stay the same after purchase. It usually checks price, contract terms, and baseline security.
That works for many software tools. It doesn't go far enough for AI.
AI systems can shift after deployment. Outputs may change because of retraining, model updates, or the way the tool is woven into clinical workflows. So while standard checks still matter, they often miss the biggest issue: what the AI might do once it's live.
There's also a data-flow problem. Sensitive patient data now moves across cloud services and connected workflows that older review processes never mapped. A standard security questionnaire may confirm encryption in transit, but that same questionnaire usually won't ask a far more urgent question: can the model produce a plausible-sounding but clinically wrong medication instruction? And if it can, does that output get auto-filled into the EHR before a human reviews it?
New Risks Procurement Teams Must Surface
Healthcare procurement teams need to surface AI-specific risks that old vendor reviews often overlook.
Opaque model logic is one of them. Many vendors use black-box models that can't clearly show why a recommendation or note was produced. That makes validation harder and weakens auditability.
PHI exposure through insecure data flows is another. AI scribes may record patient visits, transcribe them, send data through cloud-hosted services, and keep that data for model improvement. Each step creates another exposure point, and standard HIPAA checks may miss those paths [7].
Then there's unsafe output. For models used in clinical decision support, estimated hallucination rates range from 8% to 20%, depending on the model and the task [5][6]. In plain terms, the system can sound confident and still be wrong.
Biased recommendations also belong on the procurement checklist. AI scribes have been shown to be less accurate in transcribing Black patients' speech than White patients' speech [4][8]. A due-diligence process built mostly around vendor reputation and security certifications is not likely to catch that gap.
And procurement teams can't ignore hidden subcontractors and unclear accountability. A vendor might package a general-purpose large language model, depend on outside annotation firms, or use offshore teams with access to code and sometimes PHI. Those details may never appear in standard procurement documents, and old contract language often doesn't make anyone plainly accountable for them [3].
Why Healthcare AI Risk Differs from General Enterprise AI Risk
In healthcare, AI failures don't just create inconvenience. They can affect patient safety, clinical decisions, and billing integrity.
Take an AI scribe that records "metoprolol 100 mg" instead of "10 mg." If a clinician trusts that note, the error can turn into a medication mistake [2][3]. That's not the same kind of risk as a bad summary in a general business setting.
Healthcare also sits inside a dense regulatory system. HIPAA, CMS billing rules, state medical board standards, and FDA oversight for some software-as-a-medical-device categories all make documentation and decision-support outputs legally meaningful in a way that general enterprise AI outputs usually are not.
That is why patient-facing and clinical documentation use cases should be treated as a high-risk tier, not as ordinary enterprise software. Those differences shape the screening questions procurement teams need to ask before approval.
What to Evaluate Before Approving an AI-Enabled Product
Before approval, procurement needs proof on model design, data handling, clinical safety, and vendor accountability. This review shouldn't happen in a silo. Bring in security, privacy, legal, compliance, and clinical reviewers before the contract is signed.
That shift matters. It turns procurement from a simple buying checkpoint into a governance gate.
Model Transparency, Data Lineage, and PHI Handling
Start by identifying the type of AI you're dealing with.
Predictive tools need validated performance metrics. Generative tools need guardrails and mandatory clinician review before any output goes into the medical record. That's the first line between a useful tool and a risky one.
Data lineage is the next big check. Vendors should explain what trained or fine-tuned the model, including:
- Which datasets were used
- Whether PHI or personally identifiable information was involved
- How data quality and labeling were handled
You also need straight answers on data use after deployment. Ask whether customer data is retained, whether PHI is used for retraining by default, and whether users can opt out. Vendors should also confirm where PHI is stored, what encryption standards protect it in transit and at rest, how role-based access controls work, and what deletion schedules exist - and whether those schedules can be audited.
The ONC HTI-1 Final Rule requires disclosures for AI built into certified health IT. Those disclosures cover fairness, appropriateness, validity, effectiveness, and safety, which the rule calls FAVES. Use that disclosure set as the starting point for certified EHR reviews.
Once you know how the product works and what data sits behind it, the next question is simple: Can it produce biased or unsafe output?
Bias Controls, Safety Checks, Human Oversight, and Audit Trails
Don't settle for top-line accuracy. Require bias results broken out by race, sex, age, and language, not just aggregate performance.
OCR's Section 1557 guidance addresses AI-based clinical decision support tools by requiring organizations to identify and mitigate discriminatory risks and allow human override of AI decisions. That means vendors and health systems need a documented plan for nondiscrimination review and remediation.
For any AI that affects diagnosis, treatment planning, or clinical documentation, human-in-the-loop review is a must. The workflow should make it easy for a clinician to review, edit, and attest to AI-generated content before it enters the record. If that step feels clunky, people will skip it. And that's where trouble starts.
Audit trails matter just as much as review workflows. Logs should capture:
- The input
- The model version used
- The output
- Any confidence scores
- The reviewer's identity
- Whether the output was accepted, edited, or overridden
Those logs make incident investigation and regulatory reporting possible when something goes wrong.
Change Management, Third-Party Dependencies, and Accountability
AI products don't stay still after purchase. Models change, features shift, and updates can alter behavior in ways that aren't obvious on day one. Procurement should require change notices, sandbox testing for major updates, and rollback plans for failed releases.
You also need a clear map of every outside dependency. That includes each external model, cloud service, and annotation vendor. Require a dependency map, relevant certifications, and documented PHI data flows. Business associate agreements must cover every subprocessor that handles PHI.
Accountability can't be left fuzzy. Inside the organization, name owners across procurement, IT security, clinical operations, and compliance who are responsible for AI oversight. In the contract, spell out who owns data protection, uptime, incident response, and regulatory compliance at each layer of the vendor stack.
With the review criteria set, the next step is sending each product through a formal intake and assessment workflow.
sbb-itb-535baee
A Step-by-Step AI Risk Screening Workflow for Healthcare Procurement
AI Procurement Lifecycle in Healthcare: A Governance Workflow
Clear criteria help. But they don't solve the next problem: how to move products through review without clogging the process.
The fix is a tiered workflow. Low-risk tools should move fast. High-risk tools should get deeper review and tighter oversight. In practice, that means procurement needs a tiered intake path instead of sending every product through the exact same review.
Start with AI Intake and Risk Tiering
Every AI product review should start with a standard intake form. That form should capture the vendor, product, AI function, deployment model, workflow impact, PHI access, and data flow.
It also needs blunt, plain-language questions that help teams spot AI even when it's buried in product marketing. For example:
- Does this tool generate clinical notes from audio?
- Does it suggest diagnoses or flag high-risk patients?
- Does it draft messages to payers?
That kind of direct wording helps expose embedded AI that might otherwise slip through.
Once the intake is complete, use a simple scoring rubric to place each product into a risk tier.
| Risk Tier | Typical Profile | Review Depth |
|---|---|---|
| Low | De-identified operational data, no clinical impact | Security and privacy review |
| Moderate | Limited PHI, non-critical clinical workflows | Security, privacy, legal, and selective clinical review |
| High/Critical | Clinical decision support, AI scribes, generative copilots, SaMD | Full cross-functional review |
Some factors should push a product into the high tier right away. These include clinical impact, large PHI volumes, autonomous actions, external model dependencies, or possible FDA oversight. That tier then sets who reviews the request and how fast it moves.
Route Reviews Across Security, Privacy, Legal, Compliance, and Clinical Teams
After tiering, each product should follow a set review path.
Low-risk tools can move through security and privacy with less friction. Moderate-risk tools add legal review and, if outputs enter the chart, clinical review. High and critical-risk tools should go to an AI governance committee that includes clinical, compliance, risk, privacy, security, and legal.
Escalation rules need to be explicit. Committee review should kick in when there are unresolved reviewer concerns, opaque algorithms, sub-vendor dependencies on external models, or no FDA clearance where one would normally be expected.
If a tool misses standard criteria, it doesn't always need an automatic stop. In some cases, it can enter a limited pilot with tighter monitoring. The review path should fit both the product's current risk and what kind of monitoring it will need later.
Standard AI questionnaires help make the process defensible. When every vendor answers the same core AI governance questions, procurement can compare products on equal footing and show due diligence to regulators and auditors.
Centralize Assessment and Governance with the Right Tools
Once the review path is defined, the last step is keeping every intake, decision, and update in one place.
Censinet RiskOps serves as the central hub for AI vendor intake, assessments, documentation, and reporting. Standard intake forms replace ad hoc requests. Configurable workflows send high-risk tools to the right reviewers. Vendor responses, SOC 2 reports, FDA submissions, and governance decisions all sit in one system of record.
Automation can help collect questionnaires, summarize evidence, and route findings, while human review stays in place where judgment matters. A single system of record also makes approvals, exceptions, and follow-up review traceable, which helps preserve evidence for audits, reassessment, and incident response.
Contracts and Monitoring: Keeping AI Governance Enforceable After Purchase
Once an AI product gets approved, the job isn't done. This is where governance moves from review documents into contract terms and day-to-day monitoring. AI tools can change after purchase, so if you don't lock safeguards into the contract and check performance over time, that early approval can go stale fast.
Contract Terms That Address AI Risk Directly
Every AI vendor contract should tie specific safeguards to the risks those safeguards are meant to control. BAAs still matter, but AI tools need extra clauses on top of them.
One of the biggest requirements is simple: the vendor should be barred from using patient data to train or retrain models unless the patient has given authorization.[9]
Here’s how the main contract safeguards line up with the risks they address:
| Contract Safeguard | Risk It Controls |
|---|---|
| Model update notification | Unreviewed behavior changes after deployment |
| Incident reporting timelines | Delayed response to security or safety events |
| Access controls | Unauthorized PHI exposure |
| Audit rights | Inability to verify vendor compliance claims |
| PHI use restrictions | Secondary use of patient data for training |
| Retention and deletion terms | Data persistence beyond its intended purpose |
| Subcontractor disclosures | Hidden third-party exposure through sub-processors |
| Retraining responsibilities | Ambiguity over who is accountable for model changes |
| Documentation obligations | Gaps in evidence for regulatory or internal review |
The Joint Commission recommends explicit audit rights so hospitals can verify compliance and enforce remedies for breaches.[1] That matters for a plain reason: if a vendor says the right things but won't allow verification, the contract has a hole in it. Remediation and termination clauses are just as important. If monitoring turns up a safety issue, bias problem, or privacy failure, the organization needs a clear way to pause use or force corrective action.
Contract terms set the vendor's duties. Monitoring checks whether those duties still hold after deployment.
Post-Deployment Monitoring and Reassessment
Monitoring should follow a set process, not happen only when someone spots a problem. For clinical tools such as AI scribes or decision support products, teams should track output accuracy, clinician override rates, and user-reported errors on a regular schedule. For generative AI copilots, the warning signs often look different: fabricated outputs, inaccurate documentation, or missing details can point to model drift.
The risk tier assigned during intake should also drive how often a tool gets reviewed after launch. Highest-risk tools, including clinical decision support, triage AI, and patient-facing generative AI, need tighter review cycles. Lower-risk back-office tools can be reviewed less often. Still, every product should trigger an out-of-cycle reassessment when there is a model update, a reported incident, a workflow change, or unexpected performance drift.
Governance reports should show active AI systems, open exceptions, contract deviations, incidents, and overdue reviews. That kind of visibility helps stop approved tools from slowly slipping into unmanaged AI use. A single dashboard can keep reassessments, incidents, and exceptions in view between review cycles.
Conclusion: Procurement's New Role in Safe AI Adoption
Safe AI adoption in healthcare depends on four things working together: formal governance criteria used before approval, standardized screening workflows that send products to the right reviewers, enforceable contract controls that keep vendors accountable after purchase, and continuous monitoring that spots drift, incidents, and model changes before they turn into patient safety or compliance issues. Procurement teams that build these capabilities now will be in a much stronger position to adopt AI faster - and with far less risk - than teams still leaning on legacy vendor review processes.
FAQs
When should an AI tool be treated as high risk?
An AI tool should be treated as high risk when it handles PHI and can influence diagnosis, treatment, or clinical escalation decisions.
That includes tools like diagnostic AI and ambient clinical documentation tools.
The rule of thumb is simple: if an AI mistake could lead to patient harm, a wrong diagnosis, or a major workflow disruption, the tool should get a high-risk label and a rigorous review.
Who should review healthcare AI purchases?
Healthcare AI purchases should go through a multidisciplinary committee that has clear decision-making authority. That means the group doesn't just give input. It helps make the call.
The committee should include clinical leadership, IT, cybersecurity, privacy, legal, compliance, procurement, data science, and operations. Why so many teams? Because buying AI for healthcare isn't just a tech decision. It affects patient care, data use, risk, and day-to-day work across the organization.
Before any contract is signed, this group should review vendor risk, model transparency, and data handling. That early review helps keep clinical, privacy, and security stakeholders aligned across the full AI lifecycle.
How often should approved AI tools be reassessed?
Approved AI tools shouldn't be treated like a one-and-done review. They need lifecycle management over time.
High-risk AI vendors should go through a formal quarterly risk assessment. Lower-risk vendors should be reviewed annually. Teams should also revalidate tools on a regular basis for model drift, performance shifts, security incidents, and continued compliance as models change.
